| | | |
CADM
|
α-MDA-5-positive
|
|---|
|
Years of sera collection
|
Total number of DM patients (M:F)
|
Mean age at onset (range)
|
Number (%) of patients (M:F)
|
Pvalue*
|
Mean age at onset (range)
|
Number (%) of patients (M:F)
|
Pvalue**
|
Mean age at onset (range)
|
|---|
|
T1 (1994 to 1995)
|
32 (12:20)
|
47.5 (4 to 80)
|
6 (18.8%) (2:4)
|
P for difference = 0.012
|
45.5 (4 to 73)
|
2 (6.3%) (1:1%)
|
P for difference = 0.003
|
53 (43 to 63)
|
|
T2 (1996 to 2003)
|
30 (6:24)
|
50.1 (15 to 79)
|
12 (40.0%) (1:11)
|
P for trend = 0.003
|
50.7 (20 to 73)
|
10 (33.3%) (0:10)
|
P for trend = 0.001
|
48.9 (20 to 66)
|
|
T3 (2004 to 2011)
|
33 (10:23)
|
43.6 (1 to 73)
|
18 (54.5%) (5:13)
| |
40.8 (1 to 69)
|
14 (42.4%) (4:10)
| |
44.4 (11 to 58)
|
- CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; M:F, male:female; MDA-5, melanoma differentiation-associated gene 5. *Prevalence of CADM in total DM. **Prevalence of anti-MDA-5 in total DM.
